Company / Cash & Equivalents
Trevi Therapeutics, Inc. Cash & Equivalents History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$34.1M
FY2024
5-year range
$12.6M / $45.0M
FY2020-FY2024
Trend
+5.2%
vs FY2023
Sector context
#194 of 207
Health Care
What the data says
Among 207 Health Care companies, Trevi Therapeutics, Inc. is in the bottom 6% for cash & equivalents. Improved from $13M to $34M over the past 2 years.
Based on SEC 10-K filings.
$34M in FY2024 with a 5-year CAGR of -9.9%.
Improved from $13M to $34M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -2.5%
- 5-Year CAGR
- -9.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 207This company $34.1M Sector average $669.5M
▼
-94.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -9.9%, indicating a declining trend.
- In FY2024, cash & equivalents increased 5.2% year-over-year.
- Ranks #194 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $34.1M | +5.2% |
| FY2023 | $32.4M | +157.3% |
| FY2022 | $12.6M | -65.8% |
| FY2021 | $36.8M | -18.2% |
| FY2020 | $45.0M | -21.5% |
| FY2019 | $57.3M | +695.8% |
| FY2018 | $7.2M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026